SCH-58500

AXP000152.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, non-replicating, TP53)
Targets
TP53
Originator
Canji (Schering-Plough)
Sponsor
Schering-Plough

Names

NameTypeSource
SCH-58500preferred name, codecurator, ncit
ACN53codencit
rAd/p53 ambiguoussynonymncit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector encoding wild-type human p53
Transgenes
TP53
Route
intraperitoneal, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C2423

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00004080Gene Therapy in Treating Patients With Recurrent or Progressive Brain TumorsCompletedPhase 11999-12Brain and Central Nervous System Tumors
NCT00002960SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)CompletedPhase 11999-062000-0759Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
NCT00003880Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal CancerTerminatedPhase 2/31999-022001-08132Ovarian Cancer; Primary Peritoneal Cavity Cancer
Unconfirmed matches (5)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT02429037P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck CancerUnknownPhase 22015-052018-1260Advanced Head and Neck Cancerintervention named: rAd/p53
NCT02418988Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular CarcinomaUnknownPhase 22014-072017-05120Advanced Adult Hepatocellular Carcinomaname in intervention: rAd/p53
NCT01574729Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell CarcinomaUnknownPhase 22012-082015-08120Non-small Cell Lung Cancername in intervention: rAd/p53
NCT00902083rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant TumorsUnknownPhase 42009-062012-07600Advanced Oral and Maxillofacial Malignant Tumorsname in title: rAd/p53
NCT00902122rAd-p53 Gene Therapy for Advanced Malignant Thyroid TumorsUnknownPhase 42009-052012-08600Advanced Malignant Thyroid Tumorsname in intervention: rAd/p53

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 16082381Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.Cancer gene therapy2006name in title: SCH-58500
PMID 12637944Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.Cancer gene therapy2003name in abstract: SCH-58500
PMID 11844817Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2002name in abstract: SCH-58500
PMID 12082455A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.Cancer gene therapy2002cited by trial NCT00002960
PMID 12082456Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.Cancer gene therapy2002cited by trial NCT00002960
PMID 11251006Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2001name in abstract: SCH-58500
PMID 11249761Technology evaluation: Sch-58500, Canji.Current opinion in molecular therapeutics2000name in title: SCH-58500
Unconfirmed matches (3)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 32851960Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.Current gene therapy2020name in title: rAd/p53
PMID 26146864A patient with a large intrathoracic malignant schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy.Anti-cancer drugs2015name in title: rAd/p53
PMID 24479409Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial.BMC medicine2014name in title: rAd/p53

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 25364261Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.OncoTargets and therapy2014name in abstract: SCH-58500
PMID 24107178Advances in adenovirus-mediated p53 cancer gene therapy.Expert opinion on biological therapy2013name in abstract: SCH-58500
PMID 14571286Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2003name in abstract: SCH-58500
PMID 11812930Porcine toxicology studies of SCH 58500, an adenoviral vector for the p53 gene.Toxicological sciences : an official journal of the Society of Toxicology2002name in title: SCH-58500
PMID 11812931Rodent nonclinical safety evaluation studies of SCH 58500, an adenoviral vector for the p53 gene.Toxicological sciences : an official journal of the Society of Toxicology2002name in title: SCH-58500
PMID 12487057Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.Surgical oncology clinics of North America2002name in abstract: SCH-58500
PMID 12522437Intravascular adenoviral agents in cancer patients: lessons from clinical trials.Cancer gene therapy2002name in abstract: SCH-58500
PMID 10601610NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.Oncology reports2000name in abstract: SCH-58500
PMID 11032912Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.Oncology reports2000name in title: SCH-58500
PMID 11129289Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.Cancer gene therapy2000name in abstract: SCH-58500
PMID 10412949Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.Cancer chemotherapy and pharmacology1999name in abstract: SCH-58500
PMID 10595917The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.The American journal of pathology1999name in abstract: SCH-58500
Unconfirmed matches (15)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 38523676Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology.Genes & diseases2024name in title: rAd/p53
PMID 32013587Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment.Human gene therapy2020name in title: rAd/p53
PMID 33060772Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models.Scientific reports2020name in title: rAd/p53
PMID 29281902Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy.Human gene therapy2018name in title: rAd/p53
PMID 29328445The effects of interleukin 2 and rAd-p53 as a treatment for glioblastoma.Molecular medicine reports2018name in title: rAd/p53
PMID 30405797Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.Oncology letters2018name in title: rAd/p53
PMID 28621316Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.Cancer gene therapy2017name in title: rAd/p53
PMID 27446369Recurrent myoepithelial carcinoma of the submandibular gland treated by rAd-p53 combined with radiotherapy: A case report.Oncology letters2016name in title: rAd/p53
PMID 25496374Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.Expert opinion on biological therapy2015name in title: rAd/p53
PMID 22441128Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo.Gene2012name in title: rAd/p53
PMID 22090785rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy.World journal of gastroenterology2011name in title: rAd/p53
PMID 20678439[Experimental studies of rAd-p53 injection by interventional approach for the treatment of rabbit VX2 liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2010name in title: rAd/p53
PMID 17129471[The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in chemotherapy of lung squamous cell cancer].Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases2006name in title: rAd/p53
PMID 8622881Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.Oncogene1996name in abstract: ACN53
PMID 8573613Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography.Human gene therapy1995name in abstract: ACN53

NIH grants

ProjectTitleOrganisationPIYearsLinked by
M01RR000079C98-118-01: SCH58500 & chemotherapy in colorectal cancer metastatic to liverUNIVERSITY OF CALIFORNIA, SAN FRANCISCOVENOOK, ALAN PAUL1997–2003name in title: SCH-58500
M01RR000039GENE THERAPY OF PRIMARY & METASTATIC MALIGNANT LIVER TUMORS USING SCH58500EMORY UNIVERSITYSTALEY, CHARLES A1999–2002name in title: SCH-58500
M01RR000040UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORSUNIVERSITY OF PENNSYLVANIASTERMAN, DANIEL1999–2002name in abstract: SCH-58500
M01RR000865ADMINISTERING SCH 58500 TO TREAT ADENOCARCINOMA OF PROSTATEUNIVERSITY OF CALIFORNIA LOS ANGELESBELLDEGRUN, ARIE S1999–2001name in title: SCH-58500

Notes

Recombinant adenovirus-p53 from Canji/Schering-Plough, studied intraperitoneally in ovarian cancer and intratumorally in NSCLC in the late 1990s and early 2000s; no benefit shown and development stopped. A separate construct from Gendicine (AXP000141) and contusugene ladenovec (AXP000142). Also called ACN53.

How to cite

SCH-58500 (AXP000152.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000152.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.